Allurion Technologies stock soars on clinical study announcement
Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during GLP-1 therapy in combination with the Allurion Program.
Allurion Technologies Inc (ALUR) Stock: A Deeper Look at Its True Potential
Allurion Technologies Inc (ALUR) stock saw a modest uptick, ending the day at $8.69 which represents a slight increase of $4.99 or 134.86% from the prior close of $3.7. The stock opened at $16.79 and touched a low of $7.
Allurion Technologies to initiate GLP-1 study optimizing for muscle mass
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1
Allurion announces study on obesity treatment enhancement
NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), known for its efforts in combating obesity and maintaining impressive gross profit margins of 73%, disclosed today its plan to conduct a clinical study aimed at enhancing the effectiveness of obesity treatments.
Allurion stock soars 70% on weight-loss therapy update
Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.
Allurion extends rally despite $7.4M stock and warrants offering
Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...
GlobalData on MSN2d
Allurion shares soar 77% after sharing plans for GLP-1RA combo trial
Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular ...
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Allurion Technologies Shares Are Up Today: What's Going On?
Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...
bovnews3d
What’s Behind Allurion’s (ALUR) Surprising Stock Surge?
This is where Allurion’s unique approach comes into play. Previous studies have demonstrated that patients using the Allurion Gastric Balloon in combination with the Allurion Virtual Care Suite ...
Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Joplin Globe3d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with ...
Allurion Technologies to sell 1.24M shares at $6 in registered direct offering
Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors ...
Allurion Shares Surge 185% Following $7.4 Million Fundraising Announcement
Shares of Allurion Technologies ( ALUR, Financials) surged 185% to $10.54 in midday trading after the company announced plans ...